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Abstract
Background: Infection in pregnancy may be involved in the aetiology of pre-eclampsia. However, a clear association
between acute maternal infection and pre-eclampsia has not been established. We assessed whether acute urinary tract
infection, respiratory tract infection, and antibiotic drug prescriptions in pregnancy (a likely proxy for maternal infection) are
associated with an increased risk of pre-eclampsia.
Methods and Findings: We used a matched nested case-control design and data from the UK General Practice Research
Database to examine the association between maternal infection and pre-eclampsia. Primiparous women aged at least 13
years and registered with a participating practice between January 1987 and October 2007 were eligible for inclusion. We
selected all cases of pre-eclampsia and a random sample of primiparous women without pre-eclampsia (controls). Cases
(n = 1533) were individually matched with up to ten controls (n = 14236) on practice and year of delivery. We calculated
odds ratios and 95% confidence intervals for pre-eclampsia comparing women exposed and unexposed to infection using
multivariable conditional logistic regression. After adjusting for maternal age, pre-gestational hypertension, diabetes, renal
disease and multifetal gestation, the odds of pre-eclampsia were increased in women prescribed antibiotic drugs (adjusted
odds ratio 1.28;1.14–1.44) and in women with urinary tract infection (adjusted odds ratio 1.22;1.03–1.45). We found no
association with maternal respiratory tract infection (adjusted odds ratio 0.91;0.72–1.16). Further adjustment for maternal
smoking and pre-pregnancy body mass index made no difference to our findings.
Conclusions: Women who acquire a urinary infection during pregnancy, but not those who have a respiratory infection, are
at an increased risk of pre-eclampsia. Maternal antibiotic prescriptions are also associated with an increased risk. Further
research is required to elucidate the underlying mechanism of this association and to determine whether, among women
who acquire infections in pregnancy, prompt treatment or prophylaxis against infection might reduce the risk of pre-
eclampsia.
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Introduction
Pre-eclampsia is a multi-system vascular syndrome of pregnancy
defined by the gestational onset of hypertension and proteinuria,
typically occurring after 20 weeks’ gestation. It is a major cause of
maternal and perinatal morbidity and mortality worldwide, its
incidence ranging between 2% and 8% in nulliparous women. [1]
Despite advances in knowledge, we still have a limited ability to
predict or prevent pre-eclampsia. While its aetiology is generally
considered to be multifactorial, involving both maternal and
placental contributions, [2] there is increasing evidence that
inflammation plays a central pathogenic role. [3] Impaired
vascular endothelial function, which can derive from inflamma-
tion, is evident among women prior to developing pre-eclampsia.
[4] Poor placental perfusion as a result of inadequate placentation
is a key inflammatory stimulus for many women with pre-
eclampsia. However, any factor that provokes the maternal
systemic inflammatory response, such as infection, may contribute
to the overall inflammatory burden and the development of pre-
eclampsia.
A growing body of evidence suggests that infection, a common
cause of inflammation and of endothelial dysfunction, may be
involved in the aetiology of pre-eclampsia. [5] An increased risk of
pre-eclampsia associated with maternal periodontal disease has
been well-documented.[6–8] Studies based on serological markers
of chronic infections have also yielded positive findings,[9–14]
although temporal associations in these studies are uncertain.
Acute maternal infections such as urinary tract infection (UTI)
may also play a role in pre-eclampsia, possibly by amplifying the
maternal systemic inflammatory response. A meta-analysis of
observational studies examining the relationship between maternal
infections and pre-eclampsia [5] reported a summary odds ratio
for pre-eclampsia of 1.57 (95% CI 1.45–1.70) in women with UTI
in pregnancy. However, there was marked heterogeneity between
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studies and results were inconsistent. Findings from two more
recent studies are conflicting: one, a large population-based cohort
study [15] reported an increased risk of pre-eclampsia among
women with maternal UTI, while a case-control study found no
association. [16] Factors such as the timing of infection in relation
to pre-eclampsia were not investigated in these studies, and the
findings may have been confounded by renal disease, or biased by
increased ascertainment of UTI in pregnancy, particularly among
women at risk of pre-eclampsia. Data on the effects of other acute
maternal infections are lacking. Thus a clear role for acute
infection in the aetiology of pre-eclampsia has not been
established.
The large sample size afforded by the UK General Practice
Research Database (GPRD) provided a unique opportunity to
address these issues. We assessed the gestational onset of UTI, as
well as respiratory tract infection (RTI), and maternal antibiotic
prescriptions (a likely proxy for infection). Examining the role of
antibiotic prescriptions and infections in different organ systems
would, if positive, suggest that the effect of acute infection on the
risk of pre-eclampsia is generic and not specific to one type of
infection.
Methods
The General Practice Research Database
The GPRD is an electronic UK population-based primary care
database. Established in January 1987, it holds anonymised
longitudinal patient records, routinely recorded as part of patients’
normal care, for over 10 million patients registered to over 600
general practices. More than 98% of the UK population are
registered with a general practitioner (GP) and practices contrib-
uting to the database are representative of practices throughout
the UK. [17] In addition to being a rich data source, the GPRD
has high data validity. [18] Each participating practice is assigned
an ‘‘up-to-standard’’ date indicating when data recording com-
plied with specific quality measures (based on an assessment of the
completeness, continuity and plausibility of data). Data are subject
to ongoing evaluation, verification and validation procedures to
ensure they are research-quality [19].
Ethics Statement
The electronic health records used for this study comprised data
from the Full Feature GPRD obtained under licence from the UK
Medicines and Healthcare Products Regulatory Agency. GPRD
data are used extensively for public health research, and the
GPRD has stringent procedures for maintaining confidentiality of
personal data. All data provided to researchers are anonymised to
ensure that individual patients cannot be identified. In addition,
patients have the right to opt out from the use of their anonymised
data. The use of these data for this study was approved by the
Independent Scientific Advisory Committee of the GPRD
(protocol 07_094) and by the London School of Hygiene and
Tropical Medicine Ethics Committee (application number 5283).
Study Design and Participants
We used a matched nested case-control study design to examine
the association between acute maternal infections and pre-
eclampsia. Participants were derived from a source population of
all female patients registered with a practice contributing to the
GPRD between 1st January 1987 and 31st October 2007 inclusive
and who had a pregnancy during this period.
Eligibility criteria. Because pre-eclampsia usually develops
in the later stages of pregnancy, a woman must have completed
her pregnancy to have the opportunity to become a case.
Therefore, only women with a documented completed pregnancy,
defined as an end-of-pregnancy record indicating the woman had
delivered a live birth or stillbirth (e.g. ‘‘birth details’’), or was soon
to deliver (e.g. ‘‘antenatal 37 week examination’’), were potential
candidates. Pregnancies resulting in miscarriage or termination
were not included since they were likely to end before a woman
had reached the required gestational age to be at risk of being
diagnosed with pre-eclampsia. As pre-eclampsia is much more
common in nulliparous women, [20] we restricted the study
population to women with a first documented completed
pregnancy during the study period.
Women aged at least 13 years at delivery and whose data
throughout the gestational period (from conception to delivery)
were within up-to-standard follow-up were eligible for inclusion.
The follow-up criterion helped ensure that diagnoses and events
pertaining to the pregnancy were captured. Clinical entries in the
data were coded using the Oxford Medical Information System
(OXMIS) and Read coding system. We selected as potential cases
all those with a clinical diagnosis of pre-eclampsia, defined as a
Read/OXMIS code for pre-eclampsia, eclampsia or the severe
pre-eclampsia variant HELLP syndrome (hemolysis, elevated liver
enzymes, low platelets), in their first documented completed
pregnancy. We selected as potential controls a random sample of
eligible women with no diagnosis of pre-eclampsia anywhere in
their medical data. This ensured controls had no pre-eclampsia in
their first documented completed pregnancy, and no history of
pre-eclampsia possibly relating to an earlier (unrecorded) preg-
nancy.
Exclusions. To help ensure cases and controls were primip-
arous, we excluded women with evidence for an earlier completed
pregnancy (e.g. a record of ‘‘previous caesarean section’’ before
their earliest delivery record). To distinguish cases of pre-eclampsia
from women with essential or secondary hypertension which
became clinically apparent during pregnancy, we excluded women
with no evidence of high blood pressure until pregnancy but whose
hypertension did not resolve six to 12 months post-delivery. The
identification of cases and controls for inclusion in the study is
illustrated in Figure 1.
Matching. Cases were matched with controls on GP practice
to allow for variability in recording and prescribing habits between
practices, and on year of delivery (an absolute difference of up to
12 months between cases’ and controls’ estimated delivery dates)
to ensure they were contemporaneous. All possible case-control
matches were identified and up to ten controls per case were
selected at random without replacement. Although any additional
gain in power is minimal if the case-control ratio exceeds 1:4, the
number of eligible controls exceeded the number of cases by more
than twenty-fold: thus, increasing the control-per-case ratio
beyond four posed no additional cost or effort in data collection.
Dating Pregnancies
In the absence of systematically recorded information on the
exact timing of pregnancy, we used information from antenatal
records indicating gestational age, delivery records indicating the
number of days or weeks postnatal, and recorded estimates of the
expected date of delivery and first day of a woman’s last menstrual
period (LMP) to obtain our best estimates of the start and end of
each woman’s completed pregnancy. We estimated the timing of
trimesters adopting a common convention: first trimester (first day
of LMP to 13 weeks), second (weeks 14 to 26), and third (week 27
to delivery).
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Exposures
The exposure period for each participant began on the first day
of LMP and ended at the index date, defined as the date of pre-
eclampsia diagnosis (for cases). For controls, the index date was the
date they reached the same gestational age as their matched case
at pre-eclampsia diagnosis. This was to ensure the duration of the
exposure period for cases and their matched controls was
comparable.
We extracted data on Read/OXMIS codes for acute UTIs
(manifest as asymptomatic bacteriuria, cystitis, or pyelenephritis)
and RTIs (excluding non-specific or minor upper RTIs and
symptoms such as sore throat), and on antibiotic drug prescriptions
over the exposure period. When a woman had more than one
record of infection or antibiotic prescription, a minimum of 29
days between records of the same type was required for these to be
considered distinct episodes of infection (rather than repeat records
for the same infection).
Potential confounders. Data on the following potential risk
factors were extracted: maternal age; pre-gestational renal disease,
diabetes, hypertension and asthma; multifetal gestation; pre-
pregnancy body mass index (BMI); maternal smoking (a known
protective factor); previous early pregnancy loss; and assisted
reproductive technology (ART), defined as in vitro fertilization
and related techniques (including gamete intrafallopian transfer
and embryo transfer). To address the possibility that some
infections may be more likely to be recorded among women
who consult with their GP more frequently, we measured the
number of consultations and duration of follow-up each woman
had prior to pregnancy. This allowed comparison of cases’ and
controls’ pre-pregnancy consultation behaviour.
Statistical Analysis
We used multivariable conditional logistic regression to estimate
odds ratios (ORs) and 95% confidence intervals for pre-eclampsia
comparing pregnant women exposed and not exposed to each type
of infection or to antibiotic prescriptions. The primary analysis
assessed the effect of each exposure at any time during the
exposure period. Subsequent analyses explored the effects of
increasing episodes of infection over the exposure period. Potential
confounding factors associated with pre-eclampsia in crude
analyses were assessed in more complex models and retained if
they made an appreciable difference to the infection (or antibiotics)
OR. Maternal age (controlled for in five-year age groups) and pre-
existing renal disease were included in all models a priori.
Likelihood ratio tests were used to assess statistical significance.
Figure 1. Identification of study participants included in the primary analysis: A) cases (n=1533); B) controls (n =14236).
doi:10.1371/journal.pone.0073047.g001
Acute Maternal Infection and Pre-Eclampsia Risk
PLOS ONE | www.plosone.org 3 September 2013 | Volume 8 | Issue 9 | e73047
To reduce the possibility of misdiagnosis of UTI among women
with pre-eclampsia due to identification of proteinuria, we
repeated the analyses for UTI and antibiotics among cases who
developed pre-eclampsia in the third trimester and their matched
controls, and assessed the effect of exposure to UTI or antibiotics
in the first and second trimesters only versus no exposure at any
time in pregnancy. These third trimester pre-eclampsia cases were
unlikely to have proteinuria detected during the first two
trimesters, thus minimising the potential for such misclassification.
In sensitivity analyses, we excluded the following: women aged
less than 18 years as their pregnancy outcomes and underlying risk
profile may differ from older women; women with pre-existing
hypertension, to rule out the possibility of misdiagnosis of pre-
eclampsia; controls with new onset hypertension during pregnancy
which resolved shortly after delivery, as they may have had pre-
eclampsia even in the absence of a clinical diagnosis; and ART
pregnancies which may have a higher risk of developing pre-
eclampsia. To reduce the possibility that events we identified
throughout the exposure period (e.g. infections) may have referred
to past diagnoses that were recorded retrospectively within the first
few months after a patient joined a practice, we extended the up-
to-standard follow-up criterion to include only women with at least
six months up-to-standard follow-up prior to conception. To
address the possibility that pre-eclampsia diagnoses made in earlier
years were less exact, we restricted our analyses to pregnancies in
year 2000 onwards following publication of the first recommended
consensus definition of pre-eclampsia. [21] Finally, to assess
whether the effect of infection differed according to the timing of
onset of pre-eclampsia, or the severity, we conducted separate
analyses for cases with early-onset (,34 weeks’ gestation) versus
late-onset ($34 weeks’ gestation) pre-eclampsia, and for cases with
documented severe pre-eclampsia, eclampsia or HELLP syn-
drome.
Data were analysed using Stata, release 12 (StataCorp., College
Station, Texas).
Results
Data were obtained on all women with a clinical diagnosis of
pre-eclampsia during the study period (3362 potential cases) and a
large random sample of women who had a pregnancy during this
period and no recorded diagnosis of pre-eclampsia (93909
potential controls). After applying the eligibility, exclusion and
matching criteria, 1533 pre-eclampsia cases and 14236 controls
were included in the primary analysis (see Figure 1). The
commonest reason for not being eligible was uncertainty about the
timing of pregnancy. Table 1 summarizes the demographic and
risk profile of study participants. The median gestational age of
cases at pre-eclampsia diagnosis was 38.1 weeks (interquartile
range (IQR) 34.9 to 39.9 weeks), and most cases (79.5%) were late-
onset ($34 weeks’ gestation). The majority of pre-eclampsia
diagnoses were non-specific regarding severity (47.3%) or mild
(32.0%); the remaining 20.7% were severe pre-eclampsia,
eclampsia or HELLP syndrome. Cases and controls were of
similar age at delivery (median 28.3 years for cases; 28.2 years for
controls) and shared similar pre-pregnancy consultation behaviour
(median 11 consultations over 2.5 years). A higher proportion of
cases were overweight or obese (30.3%) compared to controls
(20.4%), and cases were less likely to smoke (18.5%) than controls
(23.3%).
During their first completed pregnancy, 528 (34.4%) cases and
4110 (28.9%) controls were prescribed an antibiotic drug, 182
(11.9%) cases and 1376 (9.7%) controls had one or more UTI, and
77 (5.0%) cases and 781 (5.5%) controls had one or more RTI.
The timing of each exposure by pregnancy trimester is shown in
Table 2. Less than half of women with an antibiotic prescription
in pregnancy had a record of UTI or RTI (42.8% of cases; 44.3%
of controls).
Crude and adjusted ORs for the association between maternal
infection and pre-eclampsia are summarized in Table 3. Antibi-
otic prescriptions (adjusted OR 1.28; 1.14–1.44) and UTI
(adjusted OR 1.22; 1.03–1.45) in pregnancy were associated with
an increased risk of pre-eclampsia after controlling for maternal
age; pre-gestational renal disease, diabetes and hypertension; and
multifetal gestation. We found no evidence for confounding by
prior early pregnancy loss. Findings were virtually identical when
we addressed the potential for differential misclassification of UTI
due to detection of proteinuria in cases by repeating analyses after
confining the exposure window for UTI and antibiotics to the first
two trimesters and excluding cases (n = 41) with very early onset
pre-eclampsia prior to the third trimester: adjusted OR for
antibiotics 1.26 (1.11–1.43) and UTI 1.22 (1.01–1.49). Further
adjustment for pre-pregnancy BMI and maternal smoking among
individuals with BMI and smoking data (1048 cases and 7216
controls) made no material difference to our findings (Table S1).
Women exposed to RTI in pregnancy were more likely to have
pre-existing asthma (29.5%) than women not exposed to RTI
(17.1%), and were more likely to smoke (28.6%) than those not
exposed (22.5%). We found no association between RTI and pre-
eclampsia in either the crude or adjusted analyses. The inclusion of
pre-existing asthma to our model did not alter the RTI OR.
The frequency distribution of the number of episodes (none,
one, more than one) of infection or antibiotic treatment is shown
in Table S2. No evidence of a dose-response association was
demonstrated (data not shown). Consistent with the primary
analysis, we observed an increased risk of both early- and late-
onset pre-eclampsia associated with maternal antibiotics prescrip-
tions and UTI, with no evidence for a clear difference between
these two sub-groups (Table S3). We conducted additional
sensitivity analyses as outlined in the methods. Each of these
analyses yielded estimates similar to those obtained in our primary
analysis (Table S4).
Discussion
Our study has shown that women who acquire UTI during
pregnancy, and women prescribed antibiotics during pregnancy (a
likely proxy for acute infection) are at an increased risk of pre-
eclampsia. The increased risk of pre-eclampsia developing in the
third trimester following UTI or antibiotic prescriptions in the first
two trimesters suggests that acute maternal infection may play a
role in the pathogenesis of pre-eclampsia. However, we found no
evidence for an increased risk of pre-eclampsia among women
who acquire RTI during pregnancy.
A major strength of our study is the use of a population-based
cohort of women from which we selected all cases of pre-eclampsia
in a first completed pregnancy and a random sample of
primiparous controls without pre-eclampsia. Our nested case-
control design avoids the common problem of selection bias
inherent in many case-control studies, particularly those in which
the base population giving rise to the cases is less well-defined.
Matching on GP practice allowed for variability in recording and
prescribing habits between practices, and helped ensure that cases
and controls were comparable on a range of socio-economic and
environmental indicators. The additional criterion of allowing no
more than 12 months between case and control delivery dates
ensured pregnancies within matched sets were contemporaneous.
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Another strength of this study is that we were able to include
data on a substantial number of well-known risk factors for pre-
eclampsia, some of which, most notably renal disease and diabetes,
were not accounted for in previous studies of UTI and pre-
eclampsia. [5,15,16] The associations with UTI and antibiotics
persisted even after adjustment for maternal age; pre-existing renal
disease, diabetes and hypertension; and multifetal gestation. We
cannot exclude the possibility of residual confounding if disease
risk factors were not recorded for some women; for example, the
low prevalence of pre-existing renal disease among cases (0.3%)
and controls (0.2%) suggests ascertainment of renal disease may be
limited to the more severe end of the disease spectrum. However,
this is unlikely to be a major concern since it is the more severe
disease (stages 3–5) which predisposes to pre-eclampsia, rather
than mild renal disease. [22] Missing information on maternal
smoking and pre-pregnancy BMI limited our ability to assess their
effects in the entire study population. Nevertheless, additional
adjustment for BMI and smoking made no material difference to
our findings. The similar pre-pregnancy consultation behaviour of
cases and controls suggests our findings are unlikely to be
explained by possible increased ascertainment of infection among
cases due to differential health-seeking behaviour.
We were able to restrict the study population to women in their
first documented completed pregnancy in their primary care
Table 1. Characteristics of study participants.
Characteristic n (%) Cases (N=1533) Controls (N=14236)
Maternal age at delivery (yrs)
,20 132 (8.6) 1470 (10.3)
20–24 340 (22.2) 2846 (20.0)
25–29 478 (31.2) 4492 (31.6)
30–34 406 (26.5) 3803 (26.7)
35–39 146 (9.5) 1348 (9.5)
40–44 29 (1.9) 239 (1.7)
$45 2 (0.1) 38 (0.3)
median, IQR 28.3, 23.9–32.3 28.2, 23.9–32.1
Pre-pregnancy BMI (kg/m2)
,18.5 (underweight) 26 (1.7) 526 (3.7)
18.5–25 (normal) 620 (40.4) 6618 (46.5)
25–30 (overweight) 272 (17.7) 1959 (13.8)
30+ (obese) 192 (12.5) 946 (6.7)
unknown 423 (27.6) 4187 (29.4)
median, IQR 24.1, 21.6–27.9 22.7, 20.7–25.6
Smoking status in pregnancy
non-smoker 834 (54.4) 6680 (46.9)
ex-smoker 166 (10.8) 1476 (10.4)
current smoker 283 (18.5) 3311 (23.3)
unknown 250 (16.3) 2769 (19.5)
Practice level socioeconomic statusa
IMD score [median, IQR] 16.2, 8.7–30.1 16.3, 8.4–30.2
Patient level socioeconomic status
IMD score [median, IQR] 14.3, 8.4–25.7 14.8, 8.3–26.4
unknown 744 (48.5) 6734 (47.3)
Pre-existing hypertension 161 (10.5) 875 (6.2)
Pre-existing renal disease 4 (0.3) 25 (0.2)
Pre-existing diabetes 28 (1.8) 166 (1.2)
Pre-existing asthma 291 (19.0) 2509 (17.6)
Previous miscarriage or termination 298 (19.4) 2869 (20.2)
Multiple pregnancy 25 (1.6) 121 (0.9)
ART pregnancy 11 (0.7) 84 (0.6)
Consultations with GP pre-pregnancy [median, IQR] 11, 4–27 11, 4–24
UTS follow-up pre-pregnancy (yrs) [median, IQR] 2.4, 0.9–5.1 2.5, 1.1–5.3
Abbreviations: IMD= Index of Multiple Deprivation score based on practice post-code (practice level socioeconomic status) or patient post-code (patient level
socioeconomic status). The higher the score the greater the deprivation. UTS =up-to-standard (i.e. data meeting GPRD quality standards). ART = assisted reproductive
technology.
amatching variable.
doi:10.1371/journal.pone.0073047.t001
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record, and excluded women with evidence of an earlier
(unrecorded) completed pregnancy, for example, a record
indicating parity.0 prior to the earliest delivery record. While
not guaranteeing that this was their first ever completed
pregnancy, it was likely to be the first for a large majority. In
addition, because the risk of infections is unlikely to have a strong
relationship with parity, the scope for confounding by parity is
limited. A further advantage of our approach is that it reduced the
potential for confounding by change in paternity or by inter-
pregnancy interval among multiparas [23].
While there is no universal agreement on the definition of pre-
eclampsia, [2] a diagnosis has major consequences for a pregnant
woman and is unlikely to be recorded speculatively. In 2000, the
National High Blood Pressure Education Program Working
Group developed diagnostic criteria for pre-eclampsia, [21]
recommended in the American College of Obstetricians and
Gynecologists practice guidelines for diagnosing pre-eclampsia.
[24] To improve the validity of our case definition we excluded
from the primary analysis women whose new onset hypertension
in pregnancy did not resolve following delivery, in line with this
consensus definition. While we cannot rule out the possibility of
misclassification of pre-eclampsia, this criterion helped distinguish
cases of pre-eclampsia from women with essential or secondary
hypertension that became clinically apparent during pregnancy.
Furthermore, restricting our analyses to pregnancies (and hence
pre-eclampsia diagnoses) in year 2000 onwards made no material
difference to our findings.
We used information from antenatal, perinatal and postnatal
records to estimate the date of conception, delivery, and trimesters
for all primiparous pregnancies. Although the timing may be
inexact, the same method was used for dating case and control
pregnancies, so any imprecision is likely to be non-differential. The
main consequence for this study is that some infections early in
pregnancy may have been missed if they were misclassified as
occurring prior to conception. We used the date of diagnosis (or
antibiotic prescription) rather than the date of onset of infection.
However, the majority of patients, even with upper RTIs, attend
their general practitioner within three days of onset. [25] This
small degree of imprecision is unlikely to materially affect our
results.
We recognize that not all infections lead to a GP consultation,
so some may not have been recorded. However, such infections
are more likely to be minor or asymptomatic; those severe enough
to cause systemic inflammation are more likely to result in a
consultation and be detected. We cannot rule out the possibility
that the observed associations with maternal UTI and antibiotic
prescriptions may in part be attributed to increased ascertainment
of infections among women with problematic pregnancies.
However, unlike previous studies we also investigated the effect
of acute RTI; the null effect we observed for RTI suggests that
ascertainment bias is unlikely.
Possible misclassification of UTI among women with pre-
eclampsia due to detection of proteinuria was addressed by
restricting the exposure period for infection to the first two
trimesters, prior to the onset of pre-eclampsia in the third
trimester. The resulting effect estimates for both UTI and
antibiotics were virtually identical to those obtained in the primary
analysis.
In our study, more than half of women with an antibiotic
prescription in pregnancy had no urinary or respiratory indication,
a finding which has previously been noted in primary care data.
[26] While some antibiotics might have been prescribed prophy-
lactically against recurrent infections, this is likely to be a small
minority: the majority will be given for acute infections such as
UTIs which are particularly common in pregnancy. [27]
Nevertheless, we cannot exclude the possibility that our finding
of an antibiotic effect may reflect an association with the drugs
Table 2. Frequency of maternal infection or antibiotic
treatment in pregnancy and by pregnancy trimester.
Exposure in pregnancya n (%)
Cases
(N=1533)
Controls
(N=14236)
Antibiotic treatment
Any time in pregnancy 528 (34.4) 4110 (28.9)
First trimester 221 (14.4) 1684 (11.8)
Second trimester 238 (15.5) 1952 (13.7)
Third trimester 203 (13.2) 1520 (10.7)
Urinary tract infection
Any time in pregnancy 182 (11.9) 1376 (9.7)
First trimester 64 (4.2) 463 (3.3)
Second trimester 81 (5.3) 606 (4.3)
Third trimester 57 (3.7) 487 (3.4)
Respiratory tract infection
Any time in pregnancy 77 (5.0) 781 (5.5)
First trimester 31 (2.0) 293 (2.1)
Second trimester 29 (1.9) 307 (2.2)
Third trimester 24 (1.6) 218 (1.5)
Note some women had more than one exposure in the same (or in another)
trimester.
aany time from 1st day of last menstrual period (LMP) to index date (for cases
this is the date of pre-eclampsia, for controls this is the date they reached the
same gestational age as their matched case at the case’s index date).
doi:10.1371/journal.pone.0073047.t002
Table 3. The association between maternal infection and pre-eclampsia: crude and adjusted odds ratios for matched cases
(n = 1533) and controls (n = 14236).
Exposure in pregnancya Matched crude OR (95% CI) Matched adjustedb OR (95% CI)
Antibiotic treatment 1.29 (1.15–1.44) 1.28 (1.14–1.44)
Urinary tract infection 1.23 (1.04–1.46) 1.22 (1.03–1.45)
Respiratory tract infection 0.91 (0.71–1.15) 0.91 (0.72–1.16)
aany time from 1st day of last menstrual period (LMP) to index date (for cases this is the date of pre-eclampsia, for controls this is the date they reached the same
gestational age as their matched case at the case’s index date).
bORs adjusted for maternal age; pre-gestational hypertension, diabetes and renal disease; and multifetal gestation. In addition, ORs for UTI and RTI are mutually
adjusted for.
doi:10.1371/journal.pone.0073047.t003
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themselves rather than an association with acute infection (the
main indication for their use).
Various hypotheses have been proposed to explain the
mechanism by which maternal infection may be associated with
pre-eclampsia. A key feature of pre-eclampsia is the greater
systemic inflammatory response of women who develop the
syndrome compared to women who have normal pregnancies,
[28] which suggests that inflammation may play an important role
in the pathogenesis. Acute infections such as UTI are an important
source of inflammation. Thus, the underlying mechanism of
infection may be indirect, by enhancing the maternal systemic
inflammatory response. It may also include direct effects of
infectious agents increasing the risk of acute uteroplacental
atherosis, [29] resulting in increased systemic inflammation and
vascular endothelial dysfunction preceding the clinical onset of
pre-eclampsia. Although the exact mechanism of the association is
uncertain, our finding of an increased risk of pre-eclampsia
associated with both acute UTI and maternal antibiotic prescrip-
tions lends support to the hypothesis that maternal infection may
play a pathogenic role. The relatively few individuals with more
than one episode of infection limited our ability to reliably
examine a dose-effect.
The absence of an association with RTI in our study is
intriguing and warrants further investigation, although it does not
preclude the possibility of a generic effect of infection on pre-
eclampsia risk. Our adjusted analyses suggest this finding is
unlikely to be explained by the higher prevalence of maternal
smoking (known to protect against pre-eclampsia) among women
with RTI. However, it may in part be due to incomplete
ascertainment of RTI consultations. We excluded from our
definition of RTI any non-specific RTI diagnoses (e.g. a record
of ‘‘Acute respiratory infection’’ or ‘‘Respiratory tract infection’’)
as it was unclear whether these were minor upper RTIs or more
severe lower RTIs. We expect any such non-differential misclas-
sification would lead to an underestimate of effect. The increased
risk of pre-eclampsia we observed among pregnant women with
UTI and with antibiotic prescriptions (a proxy for any acute
maternal infection, including but not restricted to UTI or RTI) is
consistent with a generic effect, suggesting as it does that the effect
may not be specific to one type of infection.
We conclude that acute maternal UTI and antibiotic drug
prescriptions in pregnancy (a likely proxy for infection) are
associated with an increased risk of pre-eclampsia. Further
research is required to elucidate the underlying mechanism of
this association and to determine whether, among women who
acquire infections in pregnancy, prompt treatment or prophylaxis
against infection might reduce the risk of pre-eclampsia.
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